Voltage-gated sodium channel alpha subunit family (Nav)

Voltage-gated sodium channels (Nav) are essential transmembrane proteins that mediate the rapid influx of sodium ions, a process fundamental to the initiation and propagation of action potentials in excitable tissues such as the brain, peripheral nerves, and heart [1.3.1, 1.3.2]. The family comprises nine alpha-subunit isoforms (Nav1.1–Nav1.9), encoded by the SCN1A through SCN11A genes, which determine the channel's pore-forming structure and pharmacological profile [1.3.4, 1.4.1]. Subtypes like Nav1.1, Nav1.2, Nav1.3, and Nav1.6 are primarily expressed in the central nervous system and are critical for neuronal excitability, while Nav1.5 is the dominant isoform in the myocardium, governing cardiac rhythm [1.1.2, 1.4.3]. Mutations in these channels are linked to a broad spectrum of 'channelopathies,' including Dravet syndrome (SCN1A), Brugada syndrome (SCN5A), and various forms of epilepsy and chronic pain [1.2.2, 1.1.4, 1.4.2]. Therapeutic agents targeting Nav channels include local anesthetics, antiarrhythmics, and anticonvulsants, which generally act as pore blockers to stabilize the inactivated state of the channel [1.3.3, 1.4.4]. Recent drug development efforts focus on achieving subtype selectivity, such as Nav1.8-specific inhibitors for pain, to avoid the systemic side effects and cardiac toxicity associated with non-selective sodium channel blockade [1.3.3, 1.4.2].

Other names

Voltage-gated sodium channelSCN familyVoltage-dependent sodium channelNav1.xVGSCSodium channel protein type alpha subunit

Voltage-gated sodium channel blocker